Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement

Michael P. Flaherty, Amr Mohsen, Joseph B. Moore, Carlo R. Bartoli, Erik Schneibel, Wasiq Rawasia, Matthew L. Williams, Kendra J. Grubb, Glenn A. Hirsch

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Data are limited regarding transcatheter aortic valve replacement (TAVR)-related thrombocytopenia (TP). We sought to thoroughly characterize the presence, clinical impact, and severity of TP associated with TAVR. Methods and Results: Data were collected from 90 patients who underwent TAVR using the Edwards SAPIEN valve (59 TF, 29 TA, 2 Tao). Platelet counts were evaluated peri-procedurally and for 8 days following TAVR. Platelet levels were compared and patients were divided into a no TP (No-TP) group 1, acquired (new) TP (NTP) group 2, pre-existing (pre-TAVR) TP (PTP) group 3, and further stratified based on the severity of TP: mild (M) TP (100-149 × 103cell/μL) and moderate-severe (MS) TP (

Original languageEnglish (US)
Pages (from-to)118-129
Number of pages12
JournalCatheterization and Cardiovascular Interventions
Volume85
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Keywords

  • Predictors
  • TAVR
  • Thrombocytopenia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Fingerprint Dive into the research topics of 'Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement'. Together they form a unique fingerprint.

Cite this